GlobalData on MSN1d
J&J and Protagonist’s icotrokinra scores in Phase IIb UC study
GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...
Johnson & Johnson reports ‘positive’ results from Phase 2b study of icotrokinra
Johnson & Johnson announced positive topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
Protagonist reports top line results from Phase 2b study of icotrokinra
Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...
Zacks.com on MSN1d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
The phase IIb ANTHEM-UC study evaluating Protagonist and JNJ's icotrokinra for treating ulcerative colitis meets the primary endpoint.
PharmExec1d
Icotrokinra Demonstrates Promise in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...
Applied Clinical Trials Online6h
Johnson & Johnson’s Icotrokinra Succeeds Across Multiple Trials in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.
Johnson & Johnson (NYSE:JNJ) Reports Positive Phase 2b Trial Results For Ulcerative Colitis Treatment
Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant announcements regarding its clinical trials, particularly the ANTHEM-UC ...